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Background
DNA vaccination is a safe and economical therapeutic
modality that has demonstrated robust elicitation of (cellu-
lar and humoral) immunity and remarkable pre-clinical
efficacy in over 30 disease models, including those of
breast, prostate and colon malignancies, multiple mye-
loma, lymphoma and fibrosarcoma. In spite of being
perched on the verge of revolutionizing the global vaccine
scenario for the last 20 years, DNA vaccines have been
relatively unsuccessful in several human trials so far, while
achieving ‘standard of care’ status in other large animals
like dogs and horses. Recent work has also shed light on
the innate adjuvant effect of double-stranded DNA and its
role in establishing an adaptive immune response, opening
several new avenues for investigation. This prevailing
scenario warrants a re-examination of the mechanism of
plasmid DNA induced immunity, with a focus on relevant
human cell systems.
Methods
Cell types enriched from primary human PBMC were
assayed for spontaneous plasmid DNA uptake, transgene
production and antigen presentation. Plasmid DNA
labeled with fluorescent peptide nucleic acid (PNA) probe
was used to detect uptake of plasmid DNA after
co-incubation. Transgene production after co-incubation
was tested using quantitative RT-PCR and flow cytometry.
Antigen presentation was examined using cells from
patients with known, pre-existing T cell responses to one
or more tumor antigens (PAP - prostatic acid phosphatase,
SSX2 - synovial sarcoma breakpoint-2). Different antigen-
presenting cell (APC) subsets were enriched and
co-incubated with T lymphocytes along with either an
empty vector or plasmid DNA encoding the relevant
tumor antigen and assayed for expansion of T cells after
7-10 days.
Results
Uptake of plasmid DNA was primarily exhibited by den-
dritic cells (CD11c+), monocyte/macrophages (CD14+)
and B lymphocytes (CD19+). Plasmid uptake was verified
by temperature-dependent kinetic studies and visualiza-
tion of internalized plasmid by image-assisted cytometry.
Transgene production was detectable only in B
lymphocytes, as assessed by qRT-PCR. T lymphocytes
co-incubated with B lymphocytes also displayed antigen-
specific proliferation and a higher fraction of tetramer-
positive CD8 T cells.
Conclusions
Though plasmid uptake is seen in multiple human cell
types, functional antigen production and presentation
occurs only in specific cell subsets. These findings suggest
that direct antigen presentation upon DNA vaccination
might be limited to B lymphocytes. Dendritic cells exhibit
robust plasmid DNA uptake, but do not encode the
antigen or prime immune responses, potentially playing a
detrimental role in immunogenicity. Therefore, these
studies highlight several latent points of intervention to
improve DNA vaccine induced immunity in humans.
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